Cart
sales@molnova.com
JNJ-7706621
CAS No. 443797-96-4
JNJ-7706621( JNJ7706621 | JNJ 7706621 )
Catalog No. M14517 CAS No. 443797-96-4
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 86 | In Stock |
|
| 5MG | 102 | In Stock |
|
| 10MG | 158 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 445 | In Stock |
|
| 100MG | 616 | In Stock |
|
| 200MG | 861 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ-7706621
-
NoteResearch use only, not for human use.
-
Brief DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
-
DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM), and no activity for Plk1 or Wee1; arrests the cell cycle at the G2-M phase; shows significant antitumor activity in tumor xenograft model.
-
In Vitro——
-
In Vivo——
-
SynonymsJNJ7706621 | JNJ 7706621
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorAuroraA|AuroraB|CDK1/CyclinB|CDK2/CyclinA|CDK2/CyclinE
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number443797-96-4
-
Formula Weight394.356
-
Molecular FormulaC15H12F2N6O3S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
-
Chemical NameBenzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Emanuel S, et al. Cancer Res. 2005 Oct 1;65(19):9038-46.
2. Huang S, et al. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
3. Seamon JA, et al. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
molnova catalog
related products
-
NU-2058
An ATP-competitive inhibitor of CDK1 and CDK2 with Ki of 5 uM and 12 uM respectively; inhibits human tumor cells with a mean GI50 of 13±7 uM.
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.
-
PF-562271
PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays.
